Innovative Dengue Vaccine Candidate Found Effective and Safe
A second dengue prevention vaccine may soon become available around the world. Japan-based Takeda announced that its dengue vaccine candidate, TAK-003, was recently found very effective in a phase 3 clinical study.
TAK-003 prevented 84% of hospitalized dengue cases and 61% of symptomatic dengue cases, with no important safety risks identified, in the overall population, including both seropositive and seronegative individuals through 54 months after vaccination.
"The burden of dengue is far-reaching, and over half of the world's population is at risk of dengue each year," said Eng Eong Ooi, Ph.D., M.D., Duke-NUS Medical School, Singapore, in a press release issue don June 9, 2022.
"There is an urgent need for impactful prevention tools to combat the disease."
TAK-003 is currently undergoing regulatory review to prevent dengue disease in children and adults in the European Union and select dengue-endemic countries.
The current U.S. FDA-approved dengue vaccine Dengvaxia is available with testing requirements.
Since June 1, 2022, the WHO recommends that dengue vaccines be given to persons with confirmed prior dengue virus infection.
From 2010 to 2020, approximately 95% of locally acquired dengue cases in the USA (n = 31,289) occurred in Puerto Rico.
In 2022, the CDC has confirmed 101 locally acquired dengue cases in Puerto Rico.
Additional dengue vaccine news is posted at Vax-Before-Travel.com/Dengue.
Note: This announcement was manually curated for mobile readers.